Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Imatinib in c-KIT Mutated Melanoma
NCT02812693Phase 2Withdrawn
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in melanoma. Planned start Nov 2016; status: withdrawn.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02812693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812693.